Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
Nuvation Bio will present new patient-reported outcomes from the pivotal TRUST-II study at ASCO 2026, showing that 88% of patients experienced improved or stable quality of life. The data highlights rapid relief from symptoms like cough and shortness of breath, alongside preserved cognitive function, differentiating IBTROZI from other ROS1 inhibitors associated with neurological impairment.
Key figures
- Drug Name
- IBTROZI (taletrectinib)
- Phase Of Trial
- Phase 2
- Trust iv enrollment target
- 180
- Patients with improved or stable qol
- 88%
- Patients with improved or stable cough or sob
- 84-96%
- Tki pretreated patients with improved or stable qol
- 93%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.